EGFR and non-small cell lung carcinoma: Notably, the treatment of the first line has been changed in the last year based on the results obtained from the FLAURA Phase III trial, which established osimertinib as a first-line treatment for EGFR mutant NSCLC, namely introducing new challenges for liquid biopsy applications.